The RePo-SUDOE project officially launches its YouTube channel, where you can now access the first sessions of the RePo-Webinars series—an online seminar cycle focused on drug repurposing, one of the most promising fields in computational medicine.
Throughout the year, this series brings together professionals and researchers who share methods, tools, and real-world case studies showing how to reuse existing drugs for new therapeutic indications, combining systems biology, artificial intelligence, and network science.
🧪 What can you already watch on the channel?
Belén introduces an approach combining systems biology and computational analysis to detect functional patterns in key molecular pathways. This strategy helps identify new therapeutic applications for already-known drugs, optimizing time and resources in drug development.
RePo-Webinars 2 & 3 | Two Python Packages for Drug Repurposing
A double session on computational tools under development:
- Carlos Loucera (Computational Medicine Platform of Andalucía) presents DREXML, a machine learning-based tool that addresses data scarcity in rare diseases, accelerating the identification of new therapeutic targets from real-world evidence.
- Andrés Aldana (Northeastern University / Harvard Medical School) introduces NetMedPy, a Python package for network medicine that analyzes how diseases alter communication within the interactome, facilitating drug repositioning through network science models.
🌍 An initiative for open knowledge in the SUDOE space
With this seminar series, RePo-SUDOE reaffirms its commitment to scientific outreach and the use of open technologies to foster drug repurposing within the SUDOE (Southwest Europe) area. The aim is to provide access to tools, methodologies, and experiences that drive research and therapeutic excellence.
📺 Catch up this summer
Three webinars are already available on our YouTube channel, and the series will continue throughout the year with more experts, topics, and innovative tools.
🔗 Explore the RePo-Webinars and subscribe to the channel here.
